|Title / Titel||Immunomodulation of neonates by virus|
|Abstract (PDF, 14 KB)|
|Original title / Originaltitel||Immunomodulation of neonates by virus / Effect of Modified Vaccinia Ankara Strain (MVA) on the unspecific immunity in neonatal animals|
|Summary / Zusammenfassung||Contents
The vaccine strain MVA was obtained after more than 570 passages of the original vaccinia virus in chicken fibroblasts. This attenuated virus is able to infect mammalian cells but the replication cycle is interrupted at a late phase. Thus, MVA is able to produce immunogenic proteins but it is unable to produce virus progeny in mammalian cells. MVA has been used as a vaccine in more than 120’000 humans without negative effects.
We will use MVA as a tool in order to investigate and understand neonatal immunity. With this virus we will accelerate the maturation of the immune system and induce a strong immunoreactivity in neonatal animals.
Some infections occur in neonates before they reach the immunological maturity necessary for vaccination. Our goal is to understand neonatal immuno-reactivity and to develop strategies for inducing strong immunocompetence in this age category. Vaccinia virus has been shown to positively influence the reactivity of the immune system. MVA and their derivatives are very safe for use in immunocompetent individuals. However, the virus produced by Bavarian Nordic (MVA-BN) was the only strain tested that did not induce disease in severely immunocompromised mice.
In the first phase we have investigated the vaccinia specific immunologic changes induced in neonatal mice (see annual report 2002). In a second phase we have now started to extend the observation to neonatal cats.
This project was completet in 2004 with the dissertation of:
Michel Erika: Vaccination of newborn cats with modified virus Ankara induces CD8-T-cells and antibodies. Universität Zürich 2004.
|Publications / Publikationen||Dissertation:
Michel Erika: Vaccination of newborn cats with modified virus Ankara induces CD8-T-cells and antibodies. Universität Zürich 2004.Weitere Informationen
|Keywords / Suchbegriffe||immunomodulation, neonates, infections, maturity, Modified Vaccinia Ankara Strain, MVA|
|Project leadership and contacts /
Projektleitung und Kontakte
|Funding source(s) /
|Private Sector (e.g. Industry)
|In collaboration with /
In Zusammenarbeit mit
|Duration of Project / Projektdauer||Aug 2001 to Dec 2004|